We want to make effective treatment optimization accessible to every European citizen
U-PGx: Ubiquitous Pharmacogenomics
THE PREPARE Clinical Study
Pharmacogenomics Educ. Material
Pharmacogenomics (PGx) is the study of genetic variability affecting an individual’s response to a drug. Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in PGx and several commercially available PGx tests, its application in routine patient care remains very limited.
The U-PGx consortium will address major challenges and obstacles for implementation of PGx testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. With the pre-emptive PGx testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive PGx-testing will be conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia).
50% of elderly patients will receive drug treatment that could be optimized via PGx within the next four years.
98% of physicians think that PGx could help to better predict drug response.
Lack of knowledge
Only 10% of physicians feel they currently have adequate knowledge and tools for PGx.
The 6th U-PGx Personalized Medicine Day will be held in Stuttgart, Germany on the 25th of February 2019.
The 5th U-PGx Personalized Medicine Day was successfully co-organized by the Golden Helix Foundation and the University of Liverpool, both partners of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353).
On October 1st 2018, the PREPARE study sites have crossed-over to the opposite arm! Sites in Spain, Greece and Slovenia have been enrolling patients for the pharmacogenomics guided prescribing arm
Six European heathcare organisations, including the European Association of Clinical Pharmacology & Therapeutics (EACPT) and the European Association of Hospital Pharmacists (EAHP), now have endorsed the pharmacogenomic guidelines used in U-PGx.
PharmGKB recently held a demonstration of the PharmGKB website as part of the U-PGx Summer School in Bonn, Germany.
We are proud to say that The Netherlands has reached its goal to recruit 600 patients in the control arm! To celebrate this, we organised a lunch (with cake!) at the LUMC for all employees working for the PREPARE study.
The PREPARE study team is proud to announce that the first 2,500 patients have been enrolled for the PREPARE study!
Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy
Fueled by the vast amount of genomic data generated in many population-scale human sequencing projects, many current research interests and efforts focus on the role of heritable genetic factors in disease and therapy.
Racial and ethnic differences in drug responses are now well studied and documented. Pharmacogenomics research seeks to unravel the genetic underpinnings of inter-individual variability with the aim of tailored-made theranostics and therapeutics.
The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen
Physicians and pharmacists increasingly recognize that pharmacogenomics (PGx)-informed prescribing and dispensing improves both the efficacy and safety of drug treatment.